Related Experiment Video
Updated: Feb 13, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell
Pulakuntla Swetha Reddy1, Kiran Bharat Lokhande2, Shuchi Nagar2
1DR Biosciences, Research and Development Center, Jayanagar 4th Block, Bangalore-560011, Karnataka, India.
Background:
Gefitinib (lressa) is the most prescribed drug, highly effective to treat nonsmall cell lung cancer; primarily it was considered that targeted therapy is a kinase inhibitor. The nonsmall cell lung cancer is caused by mutation in the Epithelial Growth Factor Receptor (EGFR) gene. Iressa works by blocking the EGFR protein that helps the cancer cell growth. EGFR protein has lead to the development of anticancer therapeutics directed against EGFR inhibitor including Gefitinib for non-small cell lung cancer.
Methods:
To explore the interaction between Gefitinib and its derivatives with crystal structure of EGFR to understand the better molecular insights interaction strategies. Molecular modeling of ligands (Gefitinib and its derivatives) was carried out by Avogadro software till atomic angle stable confirmation was obtained. The partial charges for the ligands were assigned as per standard protocol for molecular docking. All docking simulations were performed with AutoDockVina. Virtual screening was carried out based on binding energy and hydrogen bonding affinity. Molecular dynamics (MD) and Simulation EGFR were done using GROMACS 5.1.1 software to explore the interaction stability in a cell.
Results:
The stable conformation for EGFR protein trajectories were captured at various time intervals 0-20ns. Few compounds screen based on high affinity as the inhibitor for EGFR may inhibit the cell cycle signaling in non-small cell lung cancer.
Conclusion:
These result suggested a computer-aided screening approach of Gefitinib derivatives with regard to their binding to EGFR for identifying novel drugs for the treatment of non-small cell lung cancer.
Insights
This study used computational methods to screen Gefitinib derivatives for novel non-small cell lung cancer treatments. The findings suggest potential new drugs targeting the Epithelial Growth Factor Receptor (EGFR) for improved cancer therapy.
Area of Science:
- Computational chemistry
- Molecular modeling
- Drug discovery
Background:
- Gefitinib (Iressa) is a key drug for non-small cell lung cancer (NSCLC), acting as a kinase inhibitor.
- NSCLC is often driven by mutations in the Epidermal Growth Factor Receptor (EGFR) gene.
- Gefitinib functions by inhibiting the EGFR protein, crucial for cancer cell proliferation.
Purpose of the Study:
- To investigate the molecular interactions between Gefitinib derivatives and the EGFR crystal structure.
- To gain insights into molecular interaction strategies for developing novel anticancer therapeutics.
- To identify potential new drug candidates for NSCLC treatment.
Main Methods:
- Molecular modeling of Gefitinib and its derivatives using Avogadro software.
- Virtual screening via molecular docking simulations with AutoDockVina, assessing binding energy and hydrogen bonding.
- Molecular dynamics simulations using GROMACS 5.1.1 to evaluate interaction stability within a cellular context.
Main Results:
- Stable conformations of EGFR protein trajectories were observed over 0-20ns simulation time.
- Several screened compounds demonstrated high affinity as EGFR inhibitors.
- These compounds show potential to inhibit cell cycle signaling in NSCLC.
Conclusions:
- A computer-aided screening approach is effective for evaluating Gefitinib derivatives.
- This method aids in identifying novel drug candidates targeting EGFR for NSCLC.
- The study highlights potential for new therapeutic strategies against EGFR-driven cancers.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:00Molecular Models
01:47Lung Capacity
02:20Dynamic Equilibrium
03:07Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy
03:51Molecular Orbital Theory II
01:27Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...